News

Systemic Sclerosis in Young People: Imaging Improves Diagnosis

Radiologists are essential for diagnosis and further testing of pediatric patients with systemic sclerosis (SSc), according to a report published by researchers at the University of Washington Medical Center, Seattle. The paper, titled Multimodality Thoracic Imaging of Juvenile Systemic Sclerosis: Emphasis on Clinical Correlation and High-Resolution CT of Pulmonary Fibrosis,…

Eleven New Pulmonary Hypertension Care Centers Accredited by the PHA

The Pulmonary Hypertension Association (PHA) has just announced a fresh set of accredited Pulmonary Hypertension Care Centers (PHCC) as part of a program aimed towards enhancing the nation’s overall quality of healthcare and pulmonary hypertension patient outcomes. These eleven newly-accredited PHCCs have brought the total number of PHA-accredited centers…

Idiopathic PAH Vasodilator Response Reflects Blood Flow Problems

Patients with idiopathic pulmonary arterial hypertension (PAH) who responded to an acute vasodilator challenge — a clinical test that can predict how severe the disease will become — had fewer baseline blood flow abnormalities compared with non-responders. The study appeared in a research letter published in Annals…

Ascendis to Start Phase 1 Study of PAH Treatment

Ascendis Pharma A/S is beginning its phase 1 single ascending dose study on healthy participants to evaluate a potential treatment for pulmonary arterial hypertension (PAH) called TransCon Treprostinil, as announced in a press release. The investigational therapy is one of a few promising drug candidates in the clinical stage biotechnology company’s portfolio, all…

Pulmonary Arterial Hypertension Medications Studied for Drug Interactions

According to a study published by researchers at Novartis Pharma, common medications for severe pulmonary arterial hypertension interact, increasing one another’s levels when taken at the same time. However, co-administration of the medications does not appear to impact their effectiveness or increase the risk of liver problems. The study,…

Arena Pharma Begins Dosing PAH Patients with Ralinepag in Phase II Study

San Diego, California-based biopharmaceutical company Arena Pharmaceuticals, Inc. just announced they have begun dosing patients in a Phase II clinical program for ralinepag, an orally available, non-prostanoid prostacyclin (IP) receptor agonist, formulated for the treatment of pulmonary arterial hypertension (PAH). Ralinepag has performed favorably in previous preclinical and clinical…


A Conversation With Rare Disease Advocates